Iterum Therapeutics Ltd. secured $40 million in Series A funding led by Frazier Healthcare Partners together with other venture capitalists. The said fund will be used to acquire license and to enhance the development of the anti-infective drug that could counter certain bacteria's resistance to antibiotic.
pathogens
Breaking News
